Shenzhen Pan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shenzhen Pan has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Chenglong Li
Department of Vascular Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China
1 shared publication - Fangzhou Du
Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou 215163, China
1 shared publication - Hongfei Sang
Department of Vascular Surgery, The Second Affiliated Hospital of Soochow University, Suzhou 215000, China
1 shared publication - Jingzhong Zhang
School of Biomedical Engineering (Suzhou), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China
1 shared publication - Qian Wei
School of Biomedical Engineering (Suzhou), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China
1 shared publication - Qiong Deng
Department of Vascular Surgery, The Second Affiliated Hospital of Soochow University, Suzhou 215000, China
1 shared publication
Latest Publications
- Open Access
- 9 December 2024
- Published by MDPI AG in Bioengineering
- Vol. 11 (12) , 1244
The Effect of Conditioned Medium from Angiopoietin-1 Gene-Modified Mesenchymal Stem Cells on Wound Healing in a Diabetic Mouse Model
Introduction: Mesenchymal stem cells (MSCs) have been introduced as a promising treatment for diabetic wounds. The effects of stem cell therapy are thought to be caused by bioactive molecules secreted by stem cells. Stem cell-based gene therapies can target bioactive molecules. Therefore, treatment using conditioned medium (CM) derived from genetically engineered stem cells has been proposed as an alternative option for diabetic ulcer care. Methods: MSCs derived from human umbilical cords were obtained and engineered to overexpress the angiogenin-1 gene (MSCsAng1) through plasmid transfection. This study extracted conditioned medium from MSCs (MSC-CM) or MSCsAng1(MSCAng1-CM) for wound treatment applications. Via in vitro experiments, the proangiogenic effects of MSCAng1-CM were assessed via the migration and tube formation of human umbilical vein endothelial cells (HUVECs). Furthermore, the efficacy of MSCAng1-CM in promoting wound healing, re-epithelialization, hair follicle, and angiogenesis was evaluated via a diabetic mouse skin defect model. Results: In vitro assays demonstrated that MSCAng1-CM significantly enhanced HUVECs’ functions, including migration and tube formation. In vivo assays revealed that MSCAng1-CM exhibited notable advancements in healing speed, re-epithelialization, hair follicle, and angiogenesis. Conclusion: These results indicate that MSCAng1-CM can promote wound healing in diabetic mice and make the vascular structure in regenerated tissues more stable without inducing tissue fibrosis, providing a new therapeutic strategy for treating diabetic skin wounds. This provides a valuable theoretical basis for further research on regenerative medicine and cell therapy.
- 9 December 2024
- Published by MDPI AG in Bioengineering
- Vol. 11 (12) , 1244
Open AccessThe Effect of Conditioned Medium from Angiopoietin-1 Gene-Modified Mesenchymal Stem Cells on Wound Healing in a Diabetic Mouse Model
Introduction: Mesenchymal stem cells (MSCs) have been introduced as a promising treatment for diabetic wounds. The effects of stem cell therapy are thought to be caused by bioactive molecules secreted by stem cells. Stem cell-based gene therapies can target bioactive molecules. Therefore, treatment using conditioned medium (CM) derived from genetically engineered stem cells has been proposed as an alternative option for diabetic ulcer care. Methods: MSCs derived from human umbilical cords were obtained and engineered to overexpress the angiogenin-1 gene (MSCsAng1) through plasmid transfection. This study extracted conditioned medium from MSCs (MSC-CM) or MSCsAng1(MSCAng1-CM) for wound treatment applications. Via in vitro experiments, the proangiogenic effects of MSCAng1-CM were assessed via the migration and tube formation of human umbilical vein endothelial cells (HUVECs). Furthermore, the efficacy of MSCAng1-CM in promoting wound healing, re-epithelialization, hair follicle, and angiogenesis was evaluated via a diabetic mouse skin defect model. Results: In vitro assays demonstrated that MSCAng1-CM significantly enhanced HUVECs’ functions, including migration and tube formation. In vivo assays revealed that MSCAng1-CM exhibited notable advancements in healing speed, re-epithelialization, hair follicle, and angiogenesis. Conclusion: These results indicate that MSCAng1-CM can promote wound healing in diabetic mice and make the vascular structure in regenerated tissues more stable without inducing tissue fibrosis, providing a new therapeutic strategy for treating diabetic skin wounds. This provides a valuable theoretical basis for further research on regenerative medicine and cell therapy.